Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (Vitaeris)
Protocol Name: IMAGINE: Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients Sponsor: Vitaeris Indication: Post Transplant – Chronic Active Antibody Mediated Rejection Primary Investigator: Bernard Fischbach, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >